SCHEMBL2473433

SCHEMBL2473433

CCOC(=O)c1ccc(-c2noc(-c3nn(C(C)(C)C)c4c3CCC(C)(C)C4)n2)cc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.38
LMNA P02545 4/20 0.38
MEN1 O00255 3/20 0.38
MAPT P10636 3/20 0.38
KMT2A Q03164 3/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RARA P10276 1/20 0.38
RARB P10826 1/20 0.38
RARG P13631 1/20 0.38
S1PR1 P21453 9/20 0.38
S1PR3 Q99500 9/20 0.38
GLA P06280 1/20 0.37
BMP1 P13497 1/20 0.37
TGFBR1 P36897 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
FDFT1 P37268 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476438 0.89 MAPK1 (0.39) MAPK1LMNAMEN1MAPTKMT2A
SCHEMBL3462747 0.89 MAPT (0.39) MAPK1LMNAMEN1MAPTKMT2A
SCHEMBL2476280 0.88 RARA (0.38) RARARARBRARGS1PR1S1PR3
SCHEMBL2470803 0.87 NPC1 (0.39) S1PR1S1PR3
SCHEMBL3462348 0.86 MAPT (0.36) MAPK1LMNAMEN1MAPTKMT2A
SCHEMBL2473064 0.85 MAPT (0.40) MAPK1LMNAMEN1MAPTKMT2A
SCHEMBL2473119 0.84 F2RL3 (0.49) MAPK1LMNAMEN1MAPTKMT2A
SCHEMBL13262937 0.78 HDAC4 (0.40) MAPK1LMNAMAPTTSHRS1PR1
SCHEMBL2474869 0.77 S1PR1 (0.38) MAPTRARARARBRARGS1PR1
SCHEMBL2474311 0.76 NPC1 (0.39) MAPTS1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
EP-2370431-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE Almirall S.A. (ES) 2011-10-05 EP disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed
EP-2202232-A1 1,2,4-oxadiazole derivatives and their therapeutic use Laboratorios Almirall, S.A. (ES) 2010-06-30 EP disclosed
EP-2202232-A1 1,2,4-oxadiazole derivatives and their therapeutic use Laboratorios Almirall, S.A. (ES) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE S1PR1, S1PR2, S1PR3 MAPK1 2094/4885LMNA 3702/4885MEN1 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.